OverviewSuggest Edit

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.
TypePublic
Founded2015
HQSouth San Francisco, US
Websitedenalitherapeutics.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2019)261(+46%)
Revenue (FY, 2019)$26.7 M(-79%)
Share Price (Sept 2020)$36.4 (-5%)
Cybersecurity ratingAMore

Key People/Management at Denali Therapeutics

Ryan Watts

Ryan Watts

Chief Executive Officer, Director
Alexander Schuth

Alexander Schuth

COO and Head of Corporate Development
Carole Ho

Carole Ho

Chief Medical Officer
Steve Krognes

Steve Krognes

Chief Financial Officer
Cindy Dunkle

Cindy Dunkle

Chief People Officer
Dolo Diaz

Dolo Diaz

Vice President, Development Sciences
Show more

Denali Therapeutics Office Locations

Denali Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
151 Oyster Point Blvd
Show all (1)

Denali Therapeutics Financials and Metrics

Denali Therapeutics Revenue

Denali Therapeutics's revenue was reported to be $26.68 m in FY, 2019
USD

Revenue (Q2, 2020)

5.8m

Net income (Q2, 2020)

(58.8m)

EBIT (Q2, 2020)

(61.3m)

Market capitalization (21-Sept-2020)

3.9b

Closing stock price (21-Sept-2020)

36.4

Cash (30-Jun-2020)

137.2m

EV

3.8b
Denali Therapeutics's current market capitalization is $3.9 b.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

129.2m26.7m

Sales and marketing expense

5.1m11.7m15.7m

General and administrative expense

32.3m46.5m

R&D expense

11.6m75.7m74.5m143.2m193.4m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Revenue

641.0k1.6m1.2m4.2m3.6m5.8m

General and administrative expense

5.6m6.9m8.8m9.3m12.6m14.0m

R&D expense

20.8m52.1m30.3m37.4m51.0m53.2m

Operating expense total

26.4m59.0m39.2m46.7m63.6m67.1m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

39.9m218.4m77.1m79.4m

Prepaid Expenses

3.6m3.4m16.5m14.7m

Current Assets

182.0m409.6m480.8m430.0m

PP&E

15.3m14.9m25.2m46.7m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Cash

44.0m33.1m43.7m39.7m207.5m137.2m

Prepaid Expenses

4.0m4.8m8.4m14.1m17.5m9.8m

Current Assets

377.4m377.4m383.4m499.5m604.8m559.4m

PP&E

14.9m13.3m16.2m37.0m45.5m43.6m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(16.8m)(86.7m)(88.2m)(36.2m)(197.6m)

Depreciation and Amortization

121.0k1.5m3.1m8.0m

Accounts Payable

1.7m161.0k207.0k(526.0k)1.0m

Cash From Operating Activities

(15.1m)(72.4m)(76.6m)50.1m(151.6m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q1, 2020Q2, 2020

Net Income

(23.7m)(78.4m)(113.8m)(39.0m)(56.8m)(115.5m)

Depreciation and Amortization

854.0k2.7m5.0m2.4m2.1m4.3m

Accounts Payable

(951.0k)7.1m1.2m2.0m(292.0k)(744.0k)

Cash From Operating Activities

33.6m(8.2m)(43.1m)(30.3m)(54.5m)(97.8m)
Show all financial metrics

Denali Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Denali Therapeutics Online and Social Media Presence

Embed Graph

Denali Therapeutics News and Updates

MedGenome announces Strategic Collaboration in Parkinson's Disease with Denali Therapeutics

FOSTER CITY, California, Aug. 26, 2020 /PRNewswire/ -- MedGenome, a leading genomic diagnostics, research and data company based in Foster City, CA and Bangalore, India, today announced that it has formed a strategic discovery collaboration focused on novel discoveries in Parkinson's...

Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today reported financial result…

Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ("BBB") for neurodegenerative diseases, today reported financial result…

Denali Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $23.00 per share, which includes the exercise in full b…

Denali Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 7,826,087 shares of its common stock at a price to the public of $23.00 per share. All of the shares are to be sold by Denali Th…

Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2019, and pr…
Show more

Denali Therapeutics Frequently Asked Questions

  • When was Denali Therapeutics founded?

    Denali Therapeutics was founded in 2015.

  • Who are Denali Therapeutics key executives?

    Denali Therapeutics's key executives are Ryan Watts, Alexander Schuth and Carole Ho.

  • How many employees does Denali Therapeutics have?

    Denali Therapeutics has 261 employees.

  • What is Denali Therapeutics revenue?

    Latest Denali Therapeutics annual revenue is $26.7 m.

  • What is Denali Therapeutics revenue per employee?

    Latest Denali Therapeutics revenue per employee is $102.2 k.

  • Who are Denali Therapeutics competitors?

    Competitors of Denali Therapeutics include Orchard Therapeutics, Stealth BioTherapeutics and Vazyme Biotech.

  • Where is Denali Therapeutics headquarters?

    Denali Therapeutics headquarters is located at 151 Oyster Point Blvd, South San Francisco.

  • Where are Denali Therapeutics offices?

    Denali Therapeutics has an office in South San Francisco.

  • How many offices does Denali Therapeutics have?

    Denali Therapeutics has 1 office.